2 Oct

Expect a dramatic finale to the Humira patent saga

An expedited trial for Alvotech’s high strength Humira copycat could provide a dramatic ending to AbbVie’s epic series of adalimumab disputes, writes IAM life sciences editor Adam Houldsworth in this week's Saturday Opinion

Adam Houldsworth

Author | Life sciences reporter

[email protected]

Adam Houldsworth